These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

806 related items for PubMed ID: 22210563

  • 1. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study.
    Russell-Jones D, Cuddihy RM, Hanefeld M, Kumar A, González JG, Chan M, Wolka AM, Boardman MK, DURATION-4 Study Group.
    Diabetes Care; 2012 Feb; 35(2):252-8. PubMed ID: 22210563
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
    Bergenstal RM, Wysham C, Macconell L, Malloy J, Walsh B, Yan P, Wilhelm K, Malone J, Porter LE, DURATION-2 Study Group.
    Lancet; 2010 Aug 07; 376(9739):431-9. PubMed ID: 20580422
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and tolerability of exenatide once weekly versus sitagliptin in patients with type 2 diabetes mellitus: a retrospective analysis of pooled clinical trial data.
    Malloy J, Meloni A, Han J.
    Postgrad Med; 2013 May 07; 125(3):58-67. PubMed ID: 23748507
    [Abstract] [Full Text] [Related]

  • 5. Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years.
    Norwood P, Liutkus JF, Haber H, Pintilei E, Boardman MK, Trautmann ME.
    Clin Ther; 2012 Oct 07; 34(10):2082-90. PubMed ID: 23031623
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P, Sitagliptin Study 019 Group.
    Clin Ther; 2006 Oct 07; 28(10):1556-68. PubMed ID: 17157112
    [Abstract] [Full Text] [Related]

  • 9. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
    Buse JB, Bergenstal RM, Glass LC, Heilmann CR, Lewis MS, Kwan AY, Hoogwerf BJ, Rosenstock J.
    Ann Intern Med; 2011 Jan 18; 154(2):103-12. PubMed ID: 21138825
    [Abstract] [Full Text] [Related]

  • 10. A randomized non-inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with type 2 diabetes experiencing inadequate glycaemic control on metformin and sitagliptin.
    Violante R, Oliveira JH, Yoon KH, Reed VA, Yu MB, Bachmann OP, Lüdemann J, Chan JY.
    Diabet Med; 2012 Nov 18; 29(11):e417-24. PubMed ID: 22375612
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study.
    Williams-Herman D, Johnson J, Teng R, Luo E, Davies MJ, Kaufman KD, Goldstein BJ, Amatruda JM.
    Curr Med Res Opin; 2009 Mar 18; 25(3):569-83. PubMed ID: 19232032
    [Abstract] [Full Text] [Related]

  • 12. Once-weekly exenatide versus once- or twice-daily insulin detemir: randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas.
    Davies M, Heller S, Sreenan S, Sapin H, Adetunji O, Tahbaz A, Vora J.
    Diabetes Care; 2013 May 18; 36(5):1368-76. PubMed ID: 23275363
    [Abstract] [Full Text] [Related]

  • 13. Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus.
    Ryan GJ, Moniri NH, Smiley DD.
    Am J Health Syst Pharm; 2013 Jul 01; 70(13):1123-31. PubMed ID: 23784159
    [Abstract] [Full Text] [Related]

  • 14. Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes.
    DeYoung MB, MacConell L, Sarin V, Trautmann M, Herbert P.
    Diabetes Technol Ther; 2011 Nov 01; 13(11):1145-54. PubMed ID: 21751887
    [Abstract] [Full Text] [Related]

  • 15. Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment.
    Best JH, Rubin RR, Peyrot M, Li Y, Yan P, Malloy J, Garrison LP.
    Diabetes Care; 2011 Feb 01; 34(2):314-9. PubMed ID: 21270189
    [Abstract] [Full Text] [Related]

  • 16. Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes.
    Wainstein J, Katz L, Engel SS, Xu L, Golm GT, Hussain S, O'Neill EA, Kaufman KD, Goldstein BJ.
    Diabetes Obes Metab; 2012 May 01; 14(5):409-18. PubMed ID: 22059736
    [Abstract] [Full Text] [Related]

  • 17. Liraglutide achieves A1C targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 diabetes and a baseline A1C <8.0%.
    King AB, Montanya E, Pratley RE, Blonde L, Svendsen CB, Donsmark M, Sesti G.
    Endocr Pract; 2013 May 01; 19(1):64-72. PubMed ID: 23186975
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P, Sitagliptin Study 035 Group.
    Diabetes Obes Metab; 2007 Sep 01; 9(5):733-45. PubMed ID: 17593236
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes.
    Dobs AS, Goldstein BJ, Aschner P, Horton ES, Umpierrez GE, Duran L, Hill JS, Chen Y, Golm GT, Langdon RB, Williams-Herman DE, Kaufman KD, Amatruda JM, Ferreira JC.
    J Diabetes; 2013 Mar 01; 5(1):68-79. PubMed ID: 22742523
    [Abstract] [Full Text] [Related]

  • 20. Exenatide once weekly for the treatment of type 2 diabetes mellitus: clinical results in subgroups of patients using different concomitant medications.
    Pencek R, Brunell SC, Li Y, Hoogwerf BJ, Malone J.
    Postgrad Med; 2012 Jul 01; 124(4):33-40. PubMed ID: 22913892
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.